Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 3;12:775761. doi: 10.3389/fimmu.2021.775761

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Roulleaux Dugage, Nassif, Italiano and Bahleda

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Overall response rates and non-progression rates of selected prospective trials of combination treatments with immune-checkpoint inhibitors mentioned in the manuscript. ASPS, Alveolar soft-part sarcomas; LMS, Leiomyosarcoma; LPS, Liposarcoma; UPS, Undifferentiated pleomorphic sarcomas. M, months; w, weeks. Only cohorts including a minimum of three patients are reported on this graph. Non-progression rates are either three months progression-free survival rates or disease control rates at first evaluation, as reported in specific trials and mentioned throughout the manuscript.